- Cure51 adopts a unique approach by concentrating on long-term cancer survivors, aiming to understand why certain patients survive aggressive forms of cancer.
- Cure51 recently secured a €15 million seed round led by Paris-based Sofinnova Partners.
- With this funding, Cure51 intends to establish a comprehensive database that explores the factors contributing to extended cancer survival, leveraging their founders' experience in oncology centers.
Cure51, a company dedicated to cancer research, is taking a unique approach by focusing on long-term cancer survivors rather than collecting data on cancer deaths.
Recently, they secured substantial funding of €15 million from investors such as Sofinnova Partners, Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel.
With this funding, Cure51 aims to create a comprehensive database that delves into the reasons why certain cancer patients can survive for extended periods, even when faced with aggressive forms of the disease.
Founded in March 2022 by Nicolas Wolikow and Simon Istolainen, both of whom have extensive experience in renowned oncology centers, Cure51 is determined to provide a more detailed and diverse dataset compared to existing oncology databases.
The team at Cure51 strongly believes that molecular databases with multi-omics data are essential for drug discovery. Simon Turner, a partner at Sofinnova Partners, commended Cure51 for their ambitious approach and their utilization of advanced analytical techniques to unravel the mechanisms behind exceptional survival.
Edited by Shruti Thapa
